"Antineoplastic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
| Descriptor ID |
D000970
|
| MeSH Number(s) |
D27.505.954.248
|
| Concept/Terms |
Antineoplastic Agents- Antineoplastic Agents
- Agents, Antineoplastic
- Antineoplastic Drugs
- Drugs, Antineoplastic
- Antineoplastics
- Chemotherapeutic Anticancer Drug
- Drug, Chemotherapeutic Anticancer
- Antitumor Drugs
- Drugs, Antitumor
- Cancer Chemotherapy Agents
- Agents, Cancer Chemotherapy
- Chemotherapy Agents, Cancer
- Cancer Chemotherapy Drugs
- Chemotherapy Drugs, Cancer
- Drugs, Cancer Chemotherapy
- Chemotherapeutic Anticancer Agents
- Agents, Chemotherapeutic Anticancer
- Anticancer Agents
- Agents, Anticancer
- Antitumor Agents
- Agents, Antitumor
|
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Agents".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Agents".
This graph shows the total number of publications written about "Antineoplastic Agents" by people in this website by year, and whether "Antineoplastic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 13 | 2 | 15 |
| 1997 | 6 | 1 | 7 |
| 1998 | 22 | 4 | 26 |
| 1999 | 9 | 8 | 17 |
| 2000 | 17 | 6 | 23 |
| 2001 | 24 | 6 | 30 |
| 2002 | 34 | 11 | 45 |
| 2003 | 29 | 11 | 40 |
| 2004 | 35 | 12 | 47 |
| 2005 | 30 | 18 | 48 |
| 2006 | 33 | 21 | 54 |
| 2007 | 39 | 16 | 55 |
| 2008 | 31 | 18 | 49 |
| 2009 | 39 | 21 | 60 |
| 2010 | 52 | 27 | 79 |
| 2011 | 64 | 17 | 81 |
| 2012 | 56 | 28 | 84 |
| 2013 | 53 | 23 | 76 |
| 2014 | 76 | 20 | 96 |
| 2015 | 84 | 33 | 117 |
| 2016 | 59 | 31 | 90 |
| 2017 | 59 | 26 | 85 |
| 2018 | 49 | 26 | 75 |
| 2019 | 42 | 23 | 65 |
| 2020 | 38 | 23 | 61 |
| 2021 | 46 | 16 | 62 |
| 2022 | 24 | 3 | 27 |
| 2023 | 40 | 0 | 40 |
| 2024 | 20 | 24 | 44 |
| 2025 | 24 | 5 | 29 |
| 2026 | 26 | 4 | 30 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antineoplastic Agents" by people in Profiles.
-
Sunitinib in Patients With Various Solid Tumors With FGFR1/2 Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precis Oncol. 2026 Oct; 10(10):e2600454.
-
Thymol-based derivatives as anticancer agents: design, synthesis, biological evaluation, and molecular docking studies. Bioorg Chem. 2026 Nov 05; 183:110587.
-
Phase 1 Study of Anito-cel, a d-Domain BCMA CAR T Cell for Refractory or Recurrent Myeloma. N Engl J Med. 2026 Sep 24; 395(12):1180-1192.
-
PARP16 is a druggable regulator of ribosome MARylation and protein homeostasis in ovarian cancer cells. J Biol Chem. 2026 Oct; 302(10):113540.
-
Developing next-generation antibody-drug conjugates for breast cancer drug delivery: hurdles and advances in the clinic. Expert Opin Drug Deliv. 2026 Oct; 23(10):1761-1774.
-
Small-Cell Lung Cancer: Biology, Translational Science and Clinical Innovation. Drugs. 2026 Sep; 86(9):1513-1533.
-
Toxicity from asparaginase during acute lymphoblastic leukemia induction: a report from the Children's Oncology Group. Blood Adv. 2026 07 28; 10(14):4923-4930.
-
Oncology drug development in the UK: analysis of the past 25 years and focus on the 2026 reboot of the clinical trial regulatory framework. Br J Cancer. 2026 Oct; 135(8):1286-1297.
-
Genomic Subtype Influences BH3 Mimetic Drug Sensitivity and Synergy with Cytotoxic Chemotherapeutics in T-cell Acute Lymphoblastic Leukemia. Clin Cancer Res. 2026 Jul 17; 32(14):3018-3030.
-
Intratumoral and intracranial hemorrhage associated with MAPK-pathway targeted therapy: a systematic review and mechanistic synthesis. J Neurooncol. 2026 Jul 15; 178(3).